Colorectal News and Research

RSS

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Keryx Biopharmaceuticals, Inc. today announced that abstract O-0017, entitled "Subset Analysis of 5-FU Refractory Patients from a Randomized Ph II Study of Perifosine + Capecitabine (P-CAP) vs. Placebo + Capecitabine (CAP) in Patients with 2nd or 3rd Line Metastatic CRC" has been selected for oral presentation at the upcoming 12th World Congress on Gastrointestinal Cancer, to be held in Barcelona, Spain from June 30 - July 2, 2010.

30 Jun 2010

Aeterna Zentaris receives positive Scientific Advice from EMA for perifosine Phase 3 trial in colorectal cancer

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has received positive Scientific Advice from the European Medicines Agency (EMA) regarding the Phase 3 trial initiated last April for the development of its lead anticancer proprietary compound, perifosine, in refractory advanced colorectal cancer.

29 Jun 2010

Signature Dx obtains worldwide license to Affymetrix microarray technology for development of CRC tests

Affymetrix, Inc. and Signature Diagnostics AG today announced that they have signed a Powered by Affymetrix™ (PbA) agreement. Under the agreement, Signature Dx obtains a worldwide license to use Affymetrix® microarray technology to develop and commercialize diagnostic and prognostic colorectal cancer (CRC) tests.

29 Jun 2010

Scancell, immatics collaborate to develop ImmunoBody vaccines for colorectal cancer

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announces a research collaboration with immatics biotechnologies GmbH to explore the development of novel ImmunoBody® vaccines for colorectal cancer.

29 Jun 2010

Lead researchers develop a novel technique to deliver cancer drugs

A new way to deliver cancer drugs using gas bubbles and sound waves is to be developed at the University of Leeds. The project will enable highly toxic drugs to be delivered in small doses directly to tumours, where their toxicity can safely be put to good use.

29 Jun 2010

Research on safety of endoscopic piecemeal mucosal resection in treatment of large sessile colorectal polyps

Endoscopic resection of large sessile colorectal polyps is increasingly used as an alternative to surgery, but remains challenging because of its technical difficulty, the high risk of complications such as bleeding or perforation, and the possibility of coexisting malignancy.

25 Jun 2010

Latino population less likely to receive basic preventive tests, says study

"Prevention" is the new buzzword for health professionals and the new emphasis for containing future health care costs. Yet Latinos, who currently represent about 15 percent of the U.S. population, have the lowest level of preventive care of all racial and ethnic groups in the nation.

25 Jun 2010

Hydrophobic proteins may serve as biomarkers for treating colorectal cancer

Colorectal cancer, cancer of the colon and rectum, is a common cause of mortality worldwide. Statistical data showed that the number of deaths caused by colorectal cancer is increasing in both men and women.

25 Jun 2010

Patent application for tumor specific NPC-1C Antigen filed by Neogenix Oncology

Neogenix Oncology announced today that it has filed a patent application with the US Patent and Trade Office for the NPC-1C antigen. This antigen appears to be tumor specific for pancreatic and colorectal tumors.

24 Jun 2010

Nektar commences dosing in Phase 1 study of NKTR-102 in combination with 5-FU/leucovorin

Nektar Therapeutics announced today that the first patients have been dosed in a new Phase 1 dose-escalation clinical study to evaluate NKTR-102, the company's lead oncology compound, in combination with 5-fluorouracil (5-FU)/leucovorin in refractory solid tumor cancers. The study is being conducted at University Hospitals Case Medical Center of the Case Comprehensive Cancer Center in Cleveland, Ohio.

24 Jun 2010

Cancer Research UK launches new cutting-edge research centre at Imperial

A new cutting-edge cancer centre dedicated to robotic surgery, cancer imaging and drug discovery is launched today, putting London at the forefront of cancer research.

24 Jun 2010

Study examines relationship between SCIP measures and postoperative infection

A study by investigators at Case Western Reserve University School of Medicine published in this week's issue of JAMA found that public hospital comparison data reported by the U.S. Department of Health and Human Services does not accurately correlate with a patient's risk for surgical postoperative infection.

24 Jun 2010

Shift in balance between good and bad bacteria in gut could be a harbinger of colon cancer: Study

The human body contains more bacteria than it does cells. These bacterial communities can have a positive effect on our health, by training our immune systems and helping to metabolize the foods we eat. But they can also set us up to develop digestive disorders, skin diseases, and obesity.

23 Jun 2010

New presentations on neuroendocrine tumors at ESMO 12th World Congress on Gastrointestinal Cancer

Groundbreaking studies will be presented at the ESMO 12th World Congress on Gastrointestinal Cancer next week in Barcelona, Spain, including exciting new data on treatment for neuroendocrine tumors. "The presentations this year are very significant for clinicians, and outline real progress in the development of agents that are effective in managing and treating gastrointestinal diseases," says Eric Van Cutsem, MD, PhD of the University Hospital Gasthuisberg in Leuven, Belgium and Congress co-chair.

23 Jun 2010

Canada and New Zealand charities join international alliance in global fight against bowel cancer

UK charity Beating Bowel Cancer and Bowel Cancer Australia today welcomed the addition of the Colorectal Cancer Association of Canada and Beat Bowel Cancer New Zealand to the bowel cancer international alliance, Bowel Cancer International.

23 Jun 2010

Pro-Pharmaceuticals receives first purchase order for DAVANAT from PROCAPS

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced it has received its first purchase order for DAVANAT from PROCAPS S.A., a large, international pharmaceutical company based in Barranquilla, Colombia. Pro-Pharmaceuticals has received a purchase order for $200,000 which will be the upfront payment for this first shipment of DAVANAT.

22 Jun 2010

Surveillance colonoscopy is effective when targeted to high-risk patients: Study

Surveillance colonoscopy is effective and cost-effective when targeted to high-risk patients, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association Institute. However, overuse of surveillance colonoscopy could be excessively costly or even harmful.

22 Jun 2010

ASIR technique reduces already low radiation dose delivered during CTC by another 50%: Study

A newly adapted low-dose computed tomography technique called adaptive statistical iterative reconstruction can help radiologists reduce the already low radiation dose delivered during CT colonography by another 50 percent, according to a study published in the July issue of the American Journal of Roentgenology.

22 Jun 2010

CPRIT awarded $142M in grants to fund cancer research and prevention programs across the state

The Cancer Prevention and Research Institute of Texas today awarded $142 million in grants to fund innovative cancer research and prevention programs across the state. Today's announcement caps the first year of the Institute's ten year mission. Together with matching funds committed by grant recipients, more than $300 million has been invested this year in Texas' extraordinary endeavor to change the face of cancer.

19 Jun 2010

Curis reports net income of $4.8M for first-quarter 2010: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Curis Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

18 Jun 2010

Colorectal News and Research

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Aeterna Zentaris receives positive Scientific Advice from EMA for perifosine Phase 3 trial in colorectal cancer

Signature Dx obtains worldwide license to Affymetrix microarray technology for development of CRC tests

Scancell, immatics collaborate to develop ImmunoBody vaccines for colorectal cancer

Lead researchers develop a novel technique to deliver cancer drugs

Research on safety of endoscopic piecemeal mucosal resection in treatment of large sessile colorectal polyps

Latino population less likely to receive basic preventive tests, says study

Hydrophobic proteins may serve as biomarkers for treating colorectal cancer

Patent application for tumor specific NPC-1C Antigen filed by Neogenix Oncology

Nektar commences dosing in Phase 1 study of NKTR-102 in combination with 5-FU/leucovorin

Cancer Research UK launches new cutting-edge research centre at Imperial

Study examines relationship between SCIP measures and postoperative infection

Shift in balance between good and bad bacteria in gut could be a harbinger of colon cancer: Study

New presentations on neuroendocrine tumors at ESMO 12th World Congress on Gastrointestinal Cancer

Canada and New Zealand charities join international alliance in global fight against bowel cancer

Pro-Pharmaceuticals receives first purchase order for DAVANAT from PROCAPS

Surveillance colonoscopy is effective when targeted to high-risk patients: Study

ASIR technique reduces already low radiation dose delivered during CTC by another 50%: Study

CPRIT awarded $142M in grants to fund cancer research and prevention programs across the state

Curis reports net income of $4.8M for first-quarter 2010: MicroStockProfit.com

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News